Jenny Leahy

Recent experience includes advising:

• Allfunds on its recommended €5.3bn acquisition by Deutsche Börse.
• Subsea7 on the global merger control and FDI aspects of its proposed cross-border merger with Saipem.
• Smiths PLC on the global merger control and FDI aspects of the £2bn sale of Smiths Detection to CVC.
• A Global Technology Company on the CMA's cloud infrastructure market investigation, Ofcom’s cloud services market study, the EU Digital Markets Act and various global matters.
• Merck on the ex-US antitrust aspects of its $10bn acquisition of Verona Pharma plc.
• Novartis on its $12bn acquisition of Avidity Biosciences.
• AstraZeneca on its $1.1bn acquisition of Icosavax, a clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle platform.
• Roivant on the $7bn sale of its Telavant business to Roche.
• AstraZeneca on $1.2bn acquisition of Gracell Biotechnologies, a biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases.
• AstraZeneca on its $2.4bn acquisition of Fusion, a clinical-stage biopharmaceutical company developing next-generation radio-conjugates. 
• Novartis on the merger control aspects of its €2.7bn acquisition of MorphoSys.
• Zeus, a specialist provider of tubing for medical devices, on its acquisition by EQT.
• AstraZeneca on its collaboration and investment agreement with Cellectis SA. 
• Alexion, AstraZeneca Rare Disease, on its acquisition of LogicBio, a genomic medicine company.
• CVC on the merger control aspects of its €1.5bn investment in the Ligue de Football Professionnel's new commercial subsidiary.
• London Stock Exchange Group on its $27bn acquisition of Refinitiv, a financial information, data and analytics provider, which required review by 20 antitrust authorities worldwide, including in-depth merger reviews in the EU and US, as well as FDI reviews in several jurisdictions.
• Honeywell on the combination of Honeywell Quantum Solutions and Cambridge Quantum Computing and acquisition of a majority stake in the combined company.
• AstraZeneca on its $6bn global development and commercialisation agreement with Daiichi Sankyo.
• Comcast on the global merger control and public interest aspects of its £30bn public bid for Sky plc, including achieving unconditional Phase 1 clearance from the European Commission, and advising on the global merger control and public interest aspects of its $66bn bid for the global assets of 21st Century Fox.  
• Berry Global on the global merger control and competition aspects of its £5.1bn public bid for RPC Group.
• AstraZeneca on its $8.5bn strategic oncology collaboration with Merck.
• Experian plc on the CMA's Phase 2 investigation into its proposed acquisition of ClearScore.
• London Stock Exchange Group on its recommended £21bn merger with Deutsche Börse.
• Betfair on its £5bn merger with Paddy Power.
• Poundland plc on the CMA's Phase 2 investigation into its acquisition of 99p Stores.
• M&G on the FCA’s market study of the asset management industry.